
RVMD
Revolution Medicines
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RVMD
Revolution Medicines, Inc.
A clinical-stage oncology company that developing novel targeted therapies for RAS-addicted cancers
Biological Technology
Invalid Date
02/13/2020
NASDAQ Stock Exchange
534
12-31
Common stock
700 Saginaw Drive, Redwood City, California 94063
--
Revolution Medicines, Inc., founded in October 2014, is a Delaware corporation. The company is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit cutting-edge targets in RAS addictive cancer. The company has advanced structure-based drug discovery capabilities based on deep knowledge of chemical biology and cancer pharmacology and innovative proprietary technologies to create small molecules suitable for unconventional binding sites. The company's understanding of cancer's genetic drivers and adaptive resistance mechanisms, coupled with strong drug discovery and pharmacochemistry capabilities, has guided the establishment of a deep pipeline for key signaling nodes in the RAS pathway and related pathways.
Company Financials
EPS
RVMD has released its 2024 Q4 earnings. EPS was reported at -1.12, versus the expected -0.96, missing expectations. The chart below visualizes how RVMD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available